Navigation Links
United Therapeutics Receives Subpoena From Office of Inspector General

SILVER SPRING, Md., Dec. 9, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has received a subpoena from the Office of the Inspector General of the Department of Health and Human Services reflecting an investigation by the United States Department of Justice, principally represented by the United States Attorney's Office in Baltimore. The subpoena requests documents regarding Remodulin® (treprostinil) Injection, Tyvaso® (treprostinil) Inhalation Solution and Adcirca® (tadalafil) Tablets, including the company's marketing practices relating to these products. The company intends to cooperate with the investigation.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results.  Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.  We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of December 9, 2013, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

REMODULIN and TYVASO are registered trademarks of United Therapeutics Corporation.
ADCIRCA is a registered trademark of Eli Lilly and Company.

SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel Molecular Assay for Patient Screening Detects S. aureus and Newly Emerging MRSA Strains Available in the United States
2. United States Regenerative Medicine Market Analysis to 2016 Featuring Baxter, Medtronic, Stryker & Zimmer
3. Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics
4. Ten Global Health Organizations United in a Worldwide Campaign to Protect Patients from Fake Medicines
5. Surgical Notes Selected as Preferred Transcription Vendor for United Surgical Partners
6. New Drug Application For Naloxegol Accepted By United States Food And Drug Administration
7. Zevacor Molecular Awards IBA Contract to Build Only Commercial 70 MeV Cyclotron Dedicated to Medical Use in the United States
8. 2013 ISPE Facility of the Year Awards Program Names Novartiss United States Flu Cell Culture Facility as Overall Winner
9. Omnicare (NYSE: OCR) Agrees to Pay United States $120 Million to Settle False Claims Act Suit Alleging Kickbacks
10. Hospira Launches Q Core Sapphire Infusion System in the United States
11. Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
Post Your Comments:
(Date:11/30/2015)... 1, 2015 Express Scripts (NASDAQ: ESRX ) ... IMMY ) to drive access to a low-cost alternative to ... toxoplasmosis that has been recently priced out of reach for ... systems. --> --> Imprimis ... (a form of folic acid) for $1 per capsule for people ...
(Date:11/30/2015)... 2015 Die MEDTEC Japan ... für Entwicklung und Herstellung medizinischer Geräte, ... 2016 in Tokyo ... Foto:- Foto: ... Logo: --> ...
(Date:11/30/2015)... , December 1, 2015 ... adds "Endometriosis - Pipeline Review, H2 ... overview on therapeutic pipeline of Endometriosis and ... effective counter strategies to gain competitive advantage. ... targets and MOAs to produce first-in-class and ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in estate sales ... more than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live ... offer individual vision insurance plans on . The multi-carrier insurance exchange ... and review products, allowing consumers to compare, quote and match plans to meet ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (Meso Foundation) released information for caregivers and held two webinars on topics of ... on demand free of charge at . , With a loved ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a ... to announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking ... radiofrequency platform which uses temperature as a clinical endpoint. The technology has ...
(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... ... opened the driverless vehicle experience this summer, ushering in a new era of ... percent driverless and electric shuttle, will continue to offer guests an up-close look ...
Breaking Medicine News(10 mins):